Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adipose-derived mesenchymal stem cells with or without acellular dermal matrix for treatment-resistant diabetic foot ulcer
IRCT20130811014330N11Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Apr 2026
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of CSCC_ASC in diabetic foot ulcer (DFU) (3 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Wound size, IL-6 expression level and 2 more. Started Apr 2026; status: completed.
02
Drugs
CSCC_ASC
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on IRCT20130811014330N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130811014330N11.